Literature DB >> 12139123

Isolated limb perfusion: a literature review.

Jennifer Schaadt1, Richard Crowley, Danielle Miller, Maureen Kavanah.   

Abstract

Through patient education, biological research, and technological advances, the rate of many cancers in the United States of America is declining. However, the incidence of melanoma is rising steadily, as are the efforts and resources allocated to its treatment. Isolated limb perfusion, ILP, is a standard of care for treating recurrent malignant melanoma confined to a limb. Although an extracorporeal procedure, only a small percentage of perfusionists are experienced regarding ILP's indications and performance techniques. Use of ILP may increase as the incidence of melanoma increases. This two-part review is designed to familiarize the perfusionist with the procedure and the disease it treats. Part I reviews the history of isolated limb perfusion, the diagnosis and classification of malignant melanoma, and the applicability of ILP in its treatment. Part II details a procedural overview and technical considerations of the therapy from the perfusionist perspective. The review concludes with patient selection, outcomes, and the future of ILP as well as other applications for the hyperthermic regional delivery of chemotherapy using extracorporeal technology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139123

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  3 in total

1.  Percutaneous assisted venous return isolated limb perfusion.

Authors:  George Justison; Justin Westfield; Leo Carr; MaryJo Bukovic
Journal:  J Extra Corpor Technol       Date:  2009-12

2.  Multidisciplinary Perioperative Management of Hyperthermic-Isolated Limb Perfusion for Malignant Melanoma: A Case Report.

Authors:  Raghav Gupta; Himanshu P Yadav; Nishkarsh Gupta; S V S Deo; Sushma Bhatnagar
Journal:  Indian J Surg Oncol       Date:  2021-08-03

3.  Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases.

Authors:  Heiner Ruschulte; Serena Shi; William W Tseng; Kerstin Kolodzie; Philip C Crawford; Darren B Schneider; Mohammed Kashani-Sabet; David Minor; Christian Apfel; Stanley Pl Leong
Journal:  BMC Anesthesiol       Date:  2013-07-17       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.